30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Integra LifeSciences

$74.9MM, +5%

  • U.S. Extremities $31.3MM, +18%
  • U.S. Spine & Other $43.5MM, -3%


  • Private label ortho products down in low-single-digits
  • Extremities driven by regenerative medicine, foot/ankle; all franchises posting double-digit growth
  • Spine hardware sales affected by continued pricing pressure
  • Orthobiologic growth led by strong demand for Evo3
  • Reprioritization of production following product recall will affect private label business, and therefore Spine and Other for the rest of 2013